within Pharmacolibrary.Drugs.ATC.V;

model V03AB34
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0011666666666666668,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AB34</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fomepizole is a competitive inhibitor of alcohol dehydrogenase, used primarily as an antidote in poisoning with methanol or ethylene glycol. It is FDA-approved and commonly used in emergency settings to prevent toxic metabolite formation in patients who have ingested these substances.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained from healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Jairam, RK, et al., &amp; Mullangi, R (2019). Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. <i>AAPS PharmSciTech</i> 20(6) 221–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-019-1434-8&quot;>10.1208/s12249-019-1434-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31214899/&quot;>https://pubmed.ncbi.nlm.nih.gov/31214899</a></p></li><li><p>Druteika, DP, et al., &amp; Ensom, MH (2002). Role of fomepizole in the management of ethylene glycol toxicity. <i>Pharmacotherapy</i> 22(3) 365–372. DOI:<a href=&quot;https://doi.org/10.1592/phco.22.5.365.33187&quot;>10.1592/phco.22.5.365.33187</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11899949/&quot;>https://pubmed.ncbi.nlm.nih.gov/11899949</a></p></li><li><p>McMartin, KE, et al., &amp; Jacobsen, D (2012). Kinetics and metabolism of fomepizole in healthy humans. <i>Clinical toxicology (Philadelphia, Pa.)</i> 50(5) 375–383. DOI:<a href=&quot;https://doi.org/10.3109/15563650.2012.683197&quot;>10.3109/15563650.2012.683197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22554311/&quot;>https://pubmed.ncbi.nlm.nih.gov/22554311</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AB34;
